The promise of a new and better class of mental health therapies lies within the chemistry of psychedelic compounds. Our mission is to unlock it.
Toronto
Joined August 2020
- Tweets126
- Following259
- Followers265
- Likes230
Diamond is pleased to announce a strategic investment round led by First Avenue Ventures Life Science Fund I. newswire.ca/news-releases/fi…
Diamond Therapeutics retweeted
@uabnews and @DiamondThera have announced a collaboration, researching low doses of psilocybin to treat demoralization. @uabsoph professor Peter Hendricks, PhD is principle investigator in this five-week randomized clinical trial. Read more at go.uab.edu/40lKYXZ
Diamond is excited to announce our FDA-authorized clinical trial of low-dose psilocybin in collaboration with the University of Alabama at Birmingham.
newswire.ca/news-releases/di…
“Anxiety is the most common psychiatric disorder,” says Judy Blumstock, Diamond’s chief executive. “And the existing treatments aren’t satisfactory.” thestar.com/business/mars/20…
Diamond Therapeutics retweeted
Today is #BellLetsTalk Day! One of the ways we can all take action is to learn about mental health organizations creating positive change for mental health in Canada…every day.
Diamond Therapeutics retweeted
Diamond’s Phase 2 trial has been approved by Health Canada, a Phase 2 randomized, double-blind study in adult patients with Generalized Anxiety Disorder. Patients will receive repeat low doses of psilocybin administered on a take-home basis.
@DiamondThera
bit.ly/4048ppA
Diamond has received Health Canada approval to begin a Phase 2 clinical trial evaluating the safety, tolerability and efficacy of repeat low doses of psilocybin for the treatment of generalized anxiety disorder (GAD). lnkd.in/g3KpXHQU
“The purpose of this endowment is to support a professorship and to establish a world class, rigorous, empirical program of research with psychedelic substances..”griffithsfund.org
Excited to see our Phase 1 trial results and the potential for take-at-home psychedelic-derived drugs covered by Benzinga! benzinga.com/markets/cannabi…
Thank you, Dr. Emma Hapke, Dr. Daniel Rosenbaum, Dr. Susan Abbey, Nikean Foundation and @uhnfoundation, for a lively evening at The York Club.
Diamond CEO Judy Blumstock discusses all things low-dose psilocybin with The Tonic. thetonic.ca/articles/health-…
Exciting news. Wishing all GEEKs much success!!
The 2022 OBI GEEKs have been chosen! First up, we have Health Nexus Santé: The Indigenous Brain Story creating a revised curriculum for brain neuroscience training. Learn more about the 2022 GEEKs here > braininstitute.ca/geek-2022
#meettheGEEKs #indigenousbrainhealth #community
Diamond Therapeutics retweeted
New episode: Microdosing (Part 3)!
We discuss the path to FDA approval with...
Dr. Dan Karlin: MindMed (LSD for adult ADHD)
and
Dr. Mike McDonnell: Diamond Therapeutics (psilocybin for anxiety disorders)
Tune in here: businesstrip.fm/podcast/epis…
@mindmedco @DiamondThera
Diamond Therapeutics retweeted
For those looking for more information about psychedelics and psychedelic therapy, check out the Berkeley Center’s new resources website, psychedelics.berkeley.edu
Following the release of @michaelpollan 's How to Change Your Mind, researchers around the world were inundated with requests from people looking to enroll in #psychedelic #clinicaltrials psychedelicspotlight.com/?p=…
Diamond Therapeutics retweeted
In part 2 (out next week), we discuss the placebo effect and results from a placebo controlled microdosing study from @psybalazs @imperialcollege.
In part 3, we talk w/ the chief medical officers of @mindmedco @DiamondThera about going for FDA approval for microdosing.
1/5 If you’re enjoying @michaelpollan’s #HowToChangeYourMind on @netflix and want to go deeper on the science, here’s a list of #psychedelic readings authored by @DiamondThera advisors, collaborators and team members:
4/5 In this episode of @ProfDavidNutt's @Drug_Science
Podcast, @DiamondThera advisor Dr. Paul Glue discusses the development of oral ketamine and his hope that it can become an at-home vs. in-clinic treatment. youtube.com/watch?v=XPrR19Lt…
5/5
@DiamondThera science advisory chair Dr. Ed Sellers outlines the challenges of testing #psychedelics in human subjects in the International Journal of Pharmacology’s special issue on psychedelic science. sciencedirect.com/science/ar…